Published in J Biol Chem on April 30, 2001
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer (2003) 1.31
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis (2002) 0.93
Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling. Clin Exp Metastasis (2007) 0.85
Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J Ovarian Res (2010) 0.83
Korean Red Ginseng Suppresses Metastasis of Human Hepatoma SK-Hep1 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen Activator. Evid Based Complement Alternat Med (2012) 0.81
Synchronized cell attachment triggered by photo-activatable adhesive ligands allows QCM-based detection of early integrin binding. Sci Rep (2015) 0.79
Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo. Clin Exp Metastasis (2002) 0.78
Cancer and embryo expression protein 65 promotes cancer cell growth and metastasis. Oncol Lett (2015) 0.75
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem (1999) 2.76
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem (1994) 2.22
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Influence of Nitrate and Ammonia on Photosynthetic Characteristics and Leaf Anatomy of Moricandia arvensis. Plant Physiol (1982) 2.02
Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett (1991) 2.02
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des (2006) 1.88
Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene (2010) 1.86
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A (1997) 1.76
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst (2001) 1.71
The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conference. Int J Colorectal Dis (2014) 1.69
[Reliable micromethod for determination of the protein content in tissue homogenates]. Acta Biol Med Ger (1975) 1.69
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 1.66
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol (2009) 1.58
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2008) 1.54
Postmortem recovery of human immunodeficiency virus type 1 from plasma and mononuclear cells. Implications for occupational exposure. Arch Pathol Lab Med (1992) 1.53
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol (1999) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Coronary arteriopathy after lymphatic blockade: an experimental study in dogs. Lymphology (1994) 1.42
Intraoperative ultrasound does not improve detection of liver metastases in resectable pancreatic cancer. Am J Surg (1998) 1.41
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol (2005) 1.41
Isolated spastic paraparesis leading to diagnosis of Friedreich's ataxia. J Neurol Neurosurg Psychiatry (2000) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol (2001) 1.40
Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene (1997) 1.37
Cell adhesion strength is controlled by intermolecular spacing of adhesion receptors. Biophys J (2010) 1.37
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest (1998) 1.36
Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene (1997) 1.34
A review of parameters for the bioelectrical characterization of breast tissue. Ann N Y Acad Sci (1999) 1.34
Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem (1992) 1.33
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis (1999) 1.30
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis (2000) 1.30
Surgical treatment of ductal pancreatic carcinoma. Eur J Surg Oncol (1991) 1.29
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem (1991) 1.29
The solution structure of VAT-N reveals a 'missing link' in the evolution of complex enzymes from a simple betaalphabetabeta element. Curr Biol (1999) 1.28
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25
Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin (2004) 1.25
NMR investigation of the multidrug transporter EmrE, an integral membrane protein. Eur J Biochem (1998) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22
Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. Chembiochem (2000) 1.22
An efficient strategy for assignment of cross-peaks in 3D heteronuclear NOESY experiments. J Biomol NMR (1999) 1.21
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Automated backbone assignment of labeled proteins using the threshold accepting algorithm. J Biomol NMR (1998) 1.18
Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol (2009) 1.17
Methylated genes as new cancer biomarkers. Eur J Cancer (2009) 1.16
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Dynamic force spectroscopy to probe adhesion strength of living cells. Phys Rev Lett (2002) 1.16
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med (2008) 1.15
[Reduction and fixation of fractures of the neck of the radious be centro-medullary pinning. Original technic]. Rev Chir Orthop Reparatrice Appar Mot (1980) 1.14
Left superior vena cava: revisited. Eur Heart J Cardiovasc Imaging (2012) 1.13
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis (2000) 1.13
Regulation of the oxidative response of human granulocytes to chemoattractants. No evidence for stimulated traffic of redox enzymes between endo and plasma membranes. J Biol Chem (1985) 1.13
[Problems posed by carciovascular endoscopy. Experimental results]. Presse Med (1966) 1.13
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer (1998) 1.13
Measurement of the WW + WZ production cross section using the lepton + jets final state at CDF II. Phys Rev Lett (2010) 1.12
NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem (2001) 1.12
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol (1994) 1.12
Decrease in milk and blood dioxin levels over two years in a mother nursing twins: estimates of decreased maternal and increased infant dioxin body burden from nursing. Chemosphere (1996) 1.12
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol (1998) 1.12
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer (2013) 1.12
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis (1997) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res (2001) 1.10